Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 4,226 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Breast Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Background hormonal therapy; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 11
States / cities: Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more

Conditions: Dermatitis, Atopic
Interventions: GSK1070806, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: Fountain Valley, California • Pompano Beach, Florida • Fayetteville, Georgia + 3 more

Conditions: Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury
Interventions: NVG-291, Placebo Injection; Drug
Lead sponsor: NervGen Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss
Interventions: FX-322, Placebo; Drug · Other
Lead sponsor: Frequency Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Novi, Michigan • Omaha, Nebraska • Amherst, New York + 3 more

Conditions: Acute Myocardial Infarction, Congestive Heart Failure, ST-Elevation Myocardial Infarction
Interventions: IK-5001, Saline Solution; Device
Lead sponsor: Bellerophon BCM LLC; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 16
States / cities: Birmingham, Alabama • Torrance, California • Washington D.C., District of Columbia + 13 more

Conditions: Central Retinal Vein Occlusion
Interventions: Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy; Biological
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Lymphoma, Non-Hodgkin
Interventions: Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 10
States / cities: Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more

Conditions: Klinefelter Syndrome
Interventions: Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution, Placebo injectable saline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 31 Days to 90 Days · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Eosinophilic Esophagitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more

Conditions: Pain, Postoperative
Interventions: VVZ-149 Injections, Placebo; Drug
Lead sponsor: Vivozon, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 5
States / cities: Phoenix, Arizona • Anaheim, California • Dayton, Ohio + 2 more

Conditions: Healthy Volunteers
Interventions: SAR441344, placebo, Keyhole limpet hemocyanin; Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Lipoprotein Disorder
Interventions: LY3819469, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 19
States / cities: Mesa, Arizona • Pasadena, California • Santa Clarita, California + 16 more

Conditions: Huntington Disease
Interventions: RO7234292 (RG6042); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Birmingham, Alabama • La Jolla, California • Palo Alto, California + 11 more

Conditions: Multiple Myeloma
Interventions: Granulocyte colony-stimulating factor plus plerixafor, Granulocyte colony-stimulating factor plus placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 37
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 28 more

Conditions: Alexander Disease
Interventions: zilganersen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 4
States / cities: Palo Alto, California • Atlanta, Georgia • Boston, Massachusetts + 1 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: SPY072, Placebo, bimekizumab; Drug
Lead sponsor: Spyre Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Rogers, Arkansas • Irvine, California + 20 more

Conditions: HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds, Nasal Bleeding
Interventions: Bevacizumab, Placebo (Saline); Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Graves' Disease
Interventions: Experimental: YB-101, Placebo YB-101; Drug
Lead sponsor: Yarrow Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 29
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 26 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Antithymocyte Globulin, Placebo (for ATG); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 34 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Orange, California • San Francisco, California • Stanford, California + 17 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Metformin, LY2189265, Placebo (oral), Placebo (subcutaneous); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 807 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 28
States / cities: Huntsville, Alabama • Phoenix, Arizona • Buena Park, California + 25 more

Conditions: COVID-19
Interventions: Double-Blind NT-I7, Double-Blind Placebo; Drug
Lead sponsor: NeoImmuneTech; Industry
Eligibility: 19 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Bethesda, Maryland • Omaha, Nebraska

Conditions: HIV Infections
Interventions: DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more

Conditions: Ankylosing Spondylitis
Interventions: ABY-035, Placebo; Drug
Lead sponsor: Inmagene LLC; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Glendale, Arizona • Canoga Park, California • Huntington Beach, California + 12 more

Conditions: Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer, Lung Neoplasms, Oncology, Solid Tumors, Thrombocytopenia
Interventions: Romiplostim, Placebo, Gemcitabine, Carboplatin, Cisplatin; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 51
States / cities: Glendale, Arizona • Anaheim, California • Los Angeles, California + 22 more

Search by objective public record fields.

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

NVG-291 in Spinal Cord Injury Subjects

FX-322 in Adults With Severe Sensorineural Hearing Loss

IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-Operative Pain Following Abdominoplasty

Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects

A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)

A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

Intranasal Bevacizumab for HHT-Related Epistaxis

Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

STOP-T1D Low-Dose (ATG)

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)

A Trial of NT-I7 in COVID-19 (SPESELPIS)

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)